Parent firm of Doctor’s Best sees record sales for CoQ10
The company said that this was because demand was higher than supply. At the same time, capital cost had also gone down slightly.
Co-enzyme Q10 is a core business for the firm and demand was driven by consumers’ desire to prevent the occurrence of myocarditis – the inflammation of heart muscle – post COVID-19 recovery.
Other companies, such as ingredient supplier firm Kaneka, had also reported a strong uptake in China for ubiquinol, as consumers sought after supplements that could support heart health while recovering from COVID-19.
Aside from co-enzyme Q10, Xiamen Kingdomway said that there was a “big increase” of 16.82 per cent in the sales revenue of its other nutritional products to RMB$1.89bn (US$261.75m).
Revenue of Doctor’s Best, on the other hand, had also surged 28.56 per cent to RMB$956.35m (US$132.11m).
In February this year, Doctor’s Best Inc also bought over 100 per cent shares of America’s Activ Nutritional LLC from Guardion Health Sciences Inc. Activ Nutritional LLC is behind the brand supplement Viactiv.
A rapidly ageing population and the development of e-commerce were cited as the key growth factors.
“The company had boosted [the number of] short videos posted on new social media platforms for brand promotion, as well as livestreaming activities, building new communities, and stabilised user traffic on the mini applications, in turn raising brand awareness in the China market,” it said.
In total, operating revenue was Xiamen Kingdomway climbed 3.10 per cent yoy last year to RMB$ 3,102,580,918.31.
Net profit attributable to shareholders was up 7.50 per cent yoy to RMB$276,711,481.05.
Source link
Share this article:












